Relay Therapeutics (RLAY)
(Real Time Quote from BATS)
$7.63 USD
-0.36 (-4.51%)
Updated Aug 2, 2024 10:30 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Relay Therapeutics, Inc. (RLAY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.51 | $29.00 | $10.60 | 169.21% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Relay Therapeutics, Inc. comes to $21.51. The forecasts range from a low of $10.60 to a high of $29.00. The average price target represents an increase of 169.21% from the last closing price of $7.99.
Analyst Price Targets (11)
Broker Rating
Relay Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, 11 are Strong Buy, representing 91.67% of all recommendations. A month ago, Strong Buy represented 91.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RLAY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
7/18/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
6/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/7/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Hold | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
2/22/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
1/9/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 12 |
Average Target Price | $21.51 |
LT Growth Rate | 32.80% |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | -0.72 |